KRAS and non-small cell lung carcinoma: Emerging KRAS<sup>G12C</sup>inhibitors, such as adagrasib, RMC-6236, and olomorasib, show intracranial activity in KRAS<sup>G12C</sup> mutant NSCLC brain metastases, but adaptive resistance limits their effectiveness as monotherapies.